Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial.

被引：1
|
作者：
Lang, I.
Inbar, M. J.
Greil, R.
Steger, G. G.
Beslija, S.
Kahan, Z.
Eniu, A. E.
Zvirbule, Z.
Sirbu, D. E.
Zielinski, C.
机构：
[1] Natl Inst Oncol, Budapest, Hungary
[2] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel
[3] Univ Hosp Salzburg, Salzburg, Austria
[4] Med Univ Vienna, Vienna, Austria
[5] Univ Sarajevo, Inst Oncol, Clin Ctr, Sarajevo 71000, Bosnia & Herceg
[6] Univ Szeged, Szeged, Hungary
[7] Canc Inst I Chiricuta, Cluj Napoca, Romania
[8] Oncol Ctr Latvia, Riga, Latvia
[9] Med Univ Vienna, Dept Med 1, Div Clin Oncol, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.1126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1126
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Final overall survival (OS) and safety analyses of RIBBON-2, a randomized phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second-line chemotherapy (CT) for HER2-negative BEV-naive metastatic breast cancer (MBC).
    Brufsky, Adam M.
    Hurvitz, Sara A.
    Perez, Edith A.
    Yamamoto, Hideharu
    Valero, Vicente
    O'Neill, Vincent
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [42] Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
    Lam, Siu W.
    de Groot, Steffen M.
    Honkoop, Aafke H.
    Nota, Nienke M.
    Jager, A.
    van der Velden, Ankle M. T.
    Bos, Monique M. E. M.
    Linn, Sabine C.
    Van Den Bosch, J.
    Kroep, Judith R.
    Braun, J. J.
    de Haas, Richard R.
    Smorenburg, Carolien H.
    de Graaf, Hiltje
    Portielje, Johanna Elisabeth A.
    Los, Maartje
    de Gooyer, Domingo
    van Tinteren, Harm
    Boven, Epie
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] First-line bevacizumab (BEV) plus chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): Subgroup analysis of the open-label non-inferiority TURANDOT phase III trial.
    Kahan, Zsuzsanna
    Petruzelka, Lubos
    Eniu, Alexandru
    Anghel, Rodica
    Koynov, Krassimir
    Vrbanec, Damir
    Lang, Istvan
    Ahlers, Silke
    Brodowicz, Thomas
    Zielinski, Christoph
    CANCER RESEARCH, 2013, 73 (08)
  • [44] PFS by patient subgroup for standard chemotherapies in combination with bevacizumab (BV) in the first-line treatment of HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results from RIBBON-1
    Bondarenko, I.
    Glaspy, J.
    Brufsky, A.
    Lipatov, O.
    Perez, E. A.
    Chan, S.
    Zou, X.
    Phan, S. C.
    Robert, N. J.
    Dieras, V.
    EJC SUPPLEMENTS, 2010, 8 (03): : 198 - 198
  • [45] Phase II trial evaluating the combination of eribulin (E) plus bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study
    Hardy-Bessard, A-C.
    Brocard, F.
    Leheurteur, M.
    Melis, A.
    Dauba, J.
    Lortholary, A.
    You, B.
    Guardiola, E.
    Grenier, J.
    Martin-Babau, J.
    Meunier, J.
    Follana, P.
    Savoye, A-M.
    Mercier-Blas, A.
    Marti, A.
    Despax, R.
    Barbier, N.
    Gane, N.
    Ardisson, P.
    Segura-Djezzar, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [46] Weekly Paclitaxel, Capecitabine, and Bevacizumab With Maintenance Capecitabine and Bevacizumab as First-Line Therapy for Triple-Negative, Metastatic, or Locally Advanced Breast Cancer: Results From the GINECO A-TaXel Phase 2 Study
    Ferrero, Jean-Marc
    Hardy-Bessard, Anne-Claire
    Capitain, Olivier
    Lortholary, Alain
    Salles, Bruno
    Follana, Philippe
    Herve, Robert
    Deblock, Mathilde
    Dauba, Jerome
    Atlassi, Mustapha
    Largillier, Remy
    CANCER, 2016, 122 (20) : 3119 - 3126
  • [47] Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC)
    Conlin, A. K.
    Hudis, C. A.
    Bach, A.
    Moynahan, M.
    Lake, D.
    Forero-Torres, A.
    Wright, G.
    Hackney, M.
    Clawson, A.
    Seidman, A. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer
    Borson, Rachel
    Harker, Graydon
    Reeves, James
    Beck, Thaddeus
    Hager, Steven
    Horvath, William
    Jones, Michael
    Tillinghast, Guy
    Arrowsmith, Edward
    Harrer, Grant
    Kudrik, Fred J.
    Malamud, Stephen C.
    Bromund, Jane
    Zeigler, Haoyue
    Tai, Datchen Fritz
    Kornberg, Lori J.
    Obasaju, Coleman
    Orlando, Mauro
    Yardley, Denise A.
    CLINICAL BREAST CANCER, 2012, 12 (05) : 322 - 330
  • [49] Safety data from a phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer
    Danso, M.
    Blum, J.
    Robert, N.
    Krekow, L.
    Rotche, R.
    Smith, D.
    Richards, P.
    Andersone, T.
    Richards, D.
    O'Shaughnessy, J.
    EJC SUPPLEMENTS, 2008, 6 (07): : 178 - 178
  • [50] INTERIM RESULTS OF A PHASE II STUDY OF NAB-PACLITAXEL, BEVACIZUMAB, AND GEMCITABINE AS FIRST-LINE THERAPY FOR PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Gluck, S.
    Lobo, C.
    Hurley, J.
    Lopes, G.
    Reis, I.
    Seo, P.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    Tukia, K.
    ANNALS OF ONCOLOGY, 2008, 19 : 68 - 69
12345